NGLY1 and cancer: The data further suggest that the combination of NGLY1 inhibitors and proteasome inhibitors may be used to broaden the scope of proteasomal inhibition as a strategy to treat cancer, as this would not only impair the proteasome bounce-back response in cancer cells but would also potentially allow oncologists to reduce the dosage of proteasomal inhibitors used in human patients and therefore help to reduce the off-target side effects of these drugs.